Company

Albireo Pharma, Inc.

Headquarters: Boston, MA, United States

Employees: 130

CEO: Mr. Ronald H. W. Cooper

NASDAQ: ALBO

Market Cap

$910.7 Million

USD as of Jan. 1, 2023

Market Cap History

Albireo Pharma, Inc. market capitalization over time

Evolution of Albireo Pharma, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Albireo Pharma, Inc.

Detailed Description

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Albireo Pharma, Inc. has the following listings and related stock indices.


Stock: NASDAQ: ALBO wb_incandescent

Stock: FSX: BDQM wb_incandescent

Details

Headquarters:

10 Post Office Square

Suite 1000 South

Boston, MA 02109

United States

Phone: 857 254 5555